Examinando por Autor "Moreno-Tapia, Daniela"

Mostrando 1 - 2 de 2
  • No hay miniatura disponible
    Ítem
    Differences in the immune response elicited by two immunization schedules with an inactivated SARS-CoV-2 vaccine in a randomized phase 3 clinical trial
    (eLife Sciences Publications Ltd, 2022) Gálvez, Nicolás M. S.; Pacheco, Gaspar A.; Schultz, Bárbara M.; Melo-González, Felipe; Soto, Jorge A.; Duarte, Luisa F.; González, Liliana A.; Rivera-Pérez, Daniela; Ríos, Mariana; Berrios, Roslye V.; Vázquez, Yaneisi; Moreno-Tapia, Daniela; Vallejos, Omar P.; Andrade, Catalina A.; Hoppe-Elsholz, Guillermo; Iturriaga, Carolina; Urzua, Marcela; Navarrete, María S.; Rojas, Álvaro; Fasce, Rodrigo; Fernández, Jorge; Mora, Judith; Ramírez, Eugenio; Gaete-Argel, Aracelly; Acevedo, Mónica L.; Valiente-Echeverría, Fernando; Soto-Rifo, Ricardo; Weiskopf, Daniela; Grifoni, Alba; Sette, Alessandro; Zeng, Gang; Meng, Weining; González-Aramundiz, José V.; Johnson, Marina; Goldblatt, David; González, Pablo A.; Abarca, Katia; Bueno, Susan M.; Kalergis, Alexis M.
    Background: The development of vaccines to control the coronavirus disease 2019 (COVID-19) pandemic progression is a worldwide priority. CoronaVac is an inactivated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine approved for emergency use with robust efficacy and immunogenicity data reported in trials in China, Brazil, Indonesia, Turkey, and Chile. Methods: This study is a randomized, multicenter, and controlled phase 3 trial in healthy Chilean adults aged ≥18 years. Volunteers received two doses of CoronaVac separated by 2 (0–14 schedule) or 4 weeks (0–28 schedule); 2302 volunteers were enrolled, 440 were part of the immunogenicity arm, and blood samples were obtained at different times. Samples from a single center are reported. Humoral immune responses were evaluated by measuring the neutralizing capacities of circulating antibodies. Cellular immune responses were assessed by ELISPOT and flow cytometry. Correlation matrixes were performed to evaluate correlations in the data measured. Results: Both schedules exhibited robust neutralizing capacities with the response induced by the 0–28 schedule being better. No differences were found in the concentration of antibodies against the virus and different variants of concern (VOCs) between schedules. Stimulation of peripheral blood mononuclear cells (PBMCs) with Mega pools of Peptides (MPs) induced the secretion of interferon (IFN)-γ and the expression of activation induced markers in CD4+ T cells for both schedules. Correlation matrixes showed strong correlations between neutralizing antibodies and IFN-γ secretion. Conclusions: Immunization with CoronaVac in Chilean adults promotes robust cellular and humoral immune responses. The 0–28 schedule induced a stronger humoral immune response than the 0–14 schedule. © Gálvez, Pacheco, Schultz et al.
  • No hay miniatura disponible
    Ítem
    Humoral and cellular response induced by a second booster of an inactivated SARS-CoV-2 vaccine in adults
    (Elsevier B.V., 2023-05) Méndez, Constanza; Peñaloza, Hernán F.; Schultz, Bárbara M.; Piña-Iturbe, Alejandro; Ríos, Mariana; Moreno-Tapia, Daniela; Pereira-Sánchez, Patricia; Leighton, Diane; Orellana, Claudia; Covarrubias, Consuelo; Gálvez, Nicolás M.S.; Soto, Jorge A.; Duarte, Luisa F.; Rivera-Pérez, Daniela; Vázquez, Yaneisi; Cabrera, Alex; Bustos, Sergio; Iturriaga, Carolina; Urzua, Marcela; Navarrete, María S.; Rojas, Álvaro; Fasce, Rodrigo A.; Fernández, Jorge; Mora, Judith; Ramírez, Eugenio; Gaete-Argel, Aracelly; Acevedo, Mónica; Valiente-Echeverría, Fernando; Soto-Rifo, Ricardo; Weiskopf, Daniela; Grifoni, Alba; Sette, Alessandro; Zeng, Gang; Meng, Weining; Del Río, Constanza; Del Pino, Dinely; Aguirre, Natalia; Salinas, Grecia; Vega, Franco; Salgado, Acsa; Quinteros, Thomas; Ortiz, Marlene; Puente, Marcela; Muñoz, Alma; Astudillo, Patricio; Le Corre, Nicole; Potin, Marcela; Catalán, Juan; Peralta, Melan; Zamanillo, Consuelo; Keller, Nicole; Fernández, Rocío; Aljaro, Sofía; López, Sofía; González, José Tomás; Weil, Tania; Opazo, Luz; Muñoz, Paula; Estay, Inés; Cantillana, Miguel; Carrera, Liliana; Masalleras, Matías; Guzmán, Paula; Aguirre, Francisca; Cortés, Aarón; Bátiz, Luis Federico; Pérez, Javiera; Apablaza, Karen; Yates, Lorena; Valdés, María de los Ángeles; Hurtado, Bernardita; Venteneul, Veronique; Astorga, Constanza; Muñoz-Venturelli, Paula; Vial, Pablo A.; Schilling, Andrea; Pavez, Daniela; Pérez, Inia; Riviotta, Amy; González, Francisca; Urrutia, Francisca; Del Río, Alejandra; Asenjo, Claudia; Vargas, Bárbara; Castro, Francisca; Acuña, Alejandra; Guzmán, Javiera; Astudillo, Camila; Pérez, Carlos M.; Espinoza, Pilar; Martínez, Andrea; Arancibia, Marcela; Romero, Harold; Bustamante, Cecilia; Pérez, María Loreto; Uribe, Natalia; Silva, Viviana; Morice, Bernardita; Pérez, Marco; González, Marcela; Jensen, Werner; Pasten, Claudia; Aguilera, M. Fernanda; Martínez, Nataly; Molina, Camila; Arrieta, Sebastián; López, Begoña; Ortiz, Claudia; Escobar, Macarena; Bustamante, Camila; Espinoza, Marcia; Pardo, Angela; Carrasco, Alison; Montes, Miguel; Saldías, Macarena; Gutiérrez, Natalia; Sánchez, Juliette; Fuentes, Daniela; Calvo, Yolanda; Cepeda, Mariela; Lemus, Rosario; Suárez, Muriel; Armijo, Mercedes; Monsalves, Shirley; Marucich, Constance; Cornejo, Cecilia; Acosta, Ángela; Prado, Xaviera; Yáñez, Francisca; Barroeta, Marisol; López, Claudia; Donato, Paulina; Lasso, Martin; Iturrieta, María; Giraldo, Juan; Gutiérrez, Francisco; Acuña, María; Cascone, Ada; Rojas, Raymundo; Sepúlveda, Camila; Contreras, Mario; Campisto, Yessica; González, Pablo A.; Quizhpi, Zoila; López, Mariella; Pizzeghello, Vania; Silva, Stephannie; González-Aramundiz, José V.; Abarca, Katia; Melo-González, Felipe; Bueno, Susan M.; Kalergis, Alexis M.
    Background: The Omicron variant has challenged the control of the COVID-19 pandemic due to its immuno-evasive properties. The administration of a booster dose of a SARS-CoV-2 vaccine showed positive effects in the immunogenicity against SARS-CoV-2, effect that is even enhanced after the administration of a second booster. Methods: During a phase-3 clinical trial, we evaluated the effect of a second booster of CoronaVac®, an inactivated vaccine administered 6 months after the first booster, in the neutralization of SARS-CoV-2 (n = 87). In parallel, cellular immunity (n = 45) was analyzed in stimulated peripheral mononuclear cells by flow cytometry and ELISPOT. Findings: Although a 2.5-fold increase in neutralization of the ancestral SARS-CoV-2 was observed after the second booster when compared with prior its administration (Geometric mean units p < 0.0001; Geometric mean titer p = 0.0002), a poor neutralization against the Omicron variant was detected. Additionally, the activation of specific CD4+ T lymphocytes remained stable after the second booster and, importantly, equivalent activation of CD4+ T lymphocytes against the Omicron variant and the ancestral SARS-CoV-2 were found. Interpretation: Although the neutralizing response against the Omicron variant after the second booster of CoronaVac® was slightly increased, these levels are far from those observed against the ancestral SARS-CoV-2 and could most likely fail to neutralize the virus. In contrast, a robust CD4+T cell response may confer protection against the Omicron variant. Funding: The Ministry of Health, Government of Chile, the Confederation of Production and Commerce, Chile and SINOVAC Biotech. NIH NIAID. The Millennium Institute on Immunology and Immunotherapy. © 2023 The Author(s)